Bayer's High-Stakes Wait: Debt Overhang and Courtroom Gamble Weigh on Shares

Bayer stock near 200-day MA but overshadowed by €32.5B debt, Supreme Court glyphosate ruling, and new CFO's challenge of negative cash flow and litigation costs.

The stock closed at €36.06 on Friday, a fraction above its 200-day moving average of €35.99. That technical foothold offers little comfort: Bayer’s shares have shed roughly 5% since January, and the real drama is playing out far from the chart. The Leverkusen-based conglomerate is juggling two existential uncertainties — a €32.5 billion debt pile and a Supreme Court decision that could reshape its legal landscape overnight.

Fresh finance chief Judith Hartmann, who took the reins in early June, inherits a balance sheet groaning under the weight of litigation and borrowing. Net debt has swelled 9% since the start of the year, reaching €32.5 billion at the end of March. Management has ruled out a capital increase to fund legal payouts, choosing instead to tap new loans and bonds. That protects shareholders from dilution but pushes the leverage ratio ever higher — a risky "bet on the clock," as one observer put it. With Bayer forecasting negative free cash flow in 2026 and around €5 billion earmarked for litigation, Hartmann’s mandate for iron discipline is clear.

Across the Atlantic, the US Supreme Court is poised to rule on the Durnell glyphosate case. Berenberg analyst Sebastian Bray puts the odds of a Bayer victory at roughly 60%, likening the outcome to a coin toss. He has nudged his price target up from €40.00 to €40.50 while maintaining a "Hold" rating, citing better pharma margins and favourable currency tailwinds. A win could stem the tide of lawsuits that have dogged the stock for years; a loss would inflate already-plump provisions.

The courtroom drama overshadows a patchy operational picture. First-quarter group revenue rose 4% on an adjusted basis, to €13.4 billion, driven by Crop Science and Consumer Health. But the consumer health unit saw operating profit slip 1.5% to €337 million, dragging the margin to 22.6%. "Growth without margin improvement lacks quality," one analyst noted. The pharma division also disappointed: earnings before special items fell to €1.2 billion, partly because Xarelto sales plunged 33% after patent expiry as generics flooded the market.

The pipeline offers a glimmer of hope. The anticoagulant Asundexian, Bayer’s next big hope, has received a Priority Review from the FDA, putting a US approval on the table. Management has called 2026 the "last flat year" for pharma and projects a return to growth from 2027. But between regulatory green lights and blockbuster revenue lies a long, often bumpy road.

Meanwhile, the leadership shuffle continues. Samantha Avivi has been appointed global marketing chief for Consumer Health, overseeing brand strategy from the US — the unit’s most important market. In the pharma arm, investor relations chief Jost Reinhard will move to head the radiology division on 1 August 2026, succeeding Nelson Ambrogio and reporting directly to pharma boss Stefan Oelrich.

Free cash flow painted a stark picture in the first quarter, coming in at minus €2.3 billion, which Bayer blamed on settlements and legal payouts. The restructuring drive — slashing six layers of management and cutting leadership roles — is meant to save €2 billion annually by 2026, but it will take time to filter through to the bottom line.

For now, the market is pricing in none of the potential upside. A favourable Supreme Court ruling and eventual Asundexian launch could unlock a re-rating, but those catalysts lie ahead. As the stock hovers at a technical support level, patience is the only certainty — and patience, in this case, may be in short supply.